Adipose depot-specific effects of PPAR gamma agonists: a consequence of differential expression of PPAR gamma in adipose tissue depots?
Montague
Carl T
CT
AstraZeneca Pharmaceuticals, Macclesfield, UK. Carl.Montague@astrazeneca.com
D017667:Adipocytes / Q000378:metabolism; D000273:Adipose Tissue / Q000033:anatomy & histology / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000209:etiology; D003920:Diabetes Mellitus / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D003925:Diabetic Angiopathies / Q000209:etiology; D006801:Humans; D009765:Obesity; D012333:RNA, Messenger / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000037:antagonists & inhibitors* / Q000378:metabolism; D014157:Transcription Factors / Q000037:antagonists & inhibitors* / Q000378:metabolism
D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors